Equities Analysts Offer Predictions for BCAX FY2026 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings of ($1.98) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $13.01 price objective on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28).

A number of other research analysts also recently weighed in on BCAX. Wells Fargo & Company raised Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price target on the stock in a research note on Friday, May 23rd. Wall Street Zen lowered Bicara Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Friday, May 23rd. HC Wainwright decreased their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating for the company in a report on Friday, May 16th. Finally, Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.86.

Bicara Therapeutics Stock Down 0.2%

Shares of BCAX stock opened at $11.48 on Tuesday. The firm’s 50 day moving average price is $12.29 and its two-hundred day moving average price is $14.04. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $28.09.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System acquired a new stake in Bicara Therapeutics in the 4th quarter valued at $25,000. CWM LLC bought a new position in shares of Bicara Therapeutics in the 1st quarter valued at about $29,000. Spire Wealth Management acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $32,000. Finally, Legal & General Group Plc bought a new stake in Bicara Therapeutics during the fourth quarter worth about $33,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.